Analyst Price Targets — PDSB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 12, 2024 7:32 am | Mayank Mamtani | B.Riley Financial | $9.00 | $2.76 | StreetInsider | PDS Biotechnology Corp (PDSB) PT Lowered to $9 at B.Riley |
| March 28, 2024 7:41 am | Mayank Mamtani | B.Riley Financial | $11.00 | $3.85 | StreetInsider | PDS Biotechnology Corp (PDSB) PT Lowered to $11 at B.Riley on 1+ year delay |
Latest News for PDSB
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026.
PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.
PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immunotherapies for cancer, today issued a Letter to Shareholders from Frank Bedu-Addo, Ph.D.
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PDSB.
U.S. House Trading
No House trades found for PDSB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.